APA (7th ed.) Citation

Kabir Sardana, Savitha Bathula, & Ananta Khurana. (2023). Which is the ideal JAK inhibitor for alopecia areata - Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway. Wolters Kluwer Medknow Publications.

Chicago Style (17th ed.) Citation

Kabir Sardana, Savitha Bathula, and Ananta Khurana. Which Is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway. Wolters Kluwer Medknow Publications, 2023.

MLA (9th ed.) Citation

Kabir Sardana, et al. Which Is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway. Wolters Kluwer Medknow Publications, 2023.